Over 1,000 Chemotherapy Protocols And Counting

J Clin Oncol 2023 41:17_suppl, LBA8505 Chu QS IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleur

20 Nov

Multiple Myeloma

New Reference: Daratumumab with Lenalidomide and Bortezomib in 1st Line Multiple Myeloma

Lancet Haematol 2023 Oct;10(10):e825-e837 Voorhees PM Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagno

13 Jan

Non-Small Cell Lung Cancer

New Drug: Amivantamab for NSCLC

Phase 3, international, randomized trial (PAPILLON) Advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy Amivantamab + Chemoterapy (n=153) vs.

12 Dec

Breast Cancer

New Protocol: Eribulin for Breast Cancer

J Clin Oncol 2015;33(6):594-601 Kaufman PA Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast can

21 Jun

Small Cell Lung Cancer

New Indication: Repotrectinib for NTRK-Fusion Positive Solid Tumors

Advanced NTRK-fusion+ solid tumors (TRIDENT-1) TKI-naive (n=40) and TKI-pretreated (n=48)

21 Jun

Non-Small Cell Lung Cancer

New Drug: Repotrectinib for ROS1-fusion positive NSCLC

Phase 1-2 single-arm (TRIDENT-1) ROS1-fusion positive advanced NSCLC TKI-naive (n=71) - prior-TKI (n=56)

21 Jun

Uterine Cancer

New Protocol: Durvalumab with CARBOplatin and PACLitaxel for Endomterial Cancer

Randomized, double-blind phase III (DUO-E) Newly diagnosed FIGO Stage III/IV or recurrent endometrial cancer of epithelial histology Carbo/paclitaxel x 6 => Placebo maintenance (I)

14 Apr

Uterine Cancer

New Indication: Trastuzumab Deruxtecan for her2-Expressing Advanced Uterine Cancer

Phase II, multicenter, single-arm study (STATICE) Pretreated advanced or recurrent HER2-expressing UCS Trastuzumab Deruxtecan: HER 2:1+ (low group, n=10) vs. HER 22+ (high grou

14 Apr

Head and Neck Cancer

New Indication: Axitinib and Avelumab for Adenoid Cystic Carcinoma

• Open-label,single-arm, phase 2 study Pretreated metastatic or recurrent ACC Axitinib + Avelumab q28 (n=28)

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries